Intellia Therapeutics Inc

NTLA: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
CzqLOCK|W@LOCK|>gxS%Z

Intellia Earnings: Stock Crashes After Patient Dies in Key Phase 3 Study

Intellia’s shares plummeted more than 20% on Nov. 7 after news that a patient treated with its pipeline candidate Nex-Z, who had been hospitalized on Oct. 24 with elevated liver enzymes, has died. The company is investigating the liver-related events and developing a risk mitigation plan.

Sponsor Center